Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Increases By 382.4%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a significant growth in short interest during the month of May. As of May 31st, there was short interest totalling 16,400 shares, a growth of 382.4% from the May 15th total of 3,400 shares. Based on an average daily volume of 12,700 shares, the short-interest ratio is currently 1.3 days. Approximately 0.3% of the shares of the company are sold short.

PharmaCyte Biotech Stock Down 2.0%

NASDAQ PMCB opened at $1.00 on Friday. The stock’s 50-day moving average price is $1.11 and its 200-day moving average price is $1.43. PharmaCyte Biotech has a 52 week low of $1.00 and a 52 week high of $2.42. The company has a market capitalization of $6.86 million, a P/E ratio of 1.89 and a beta of -0.44.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings data on Monday, March 17th. The company reported ($0.10) earnings per share (EPS) for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.